il-23
Recombinant proteinexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Oct 4, 2024 (NCT06274554)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 3 Sponsor(trial)
Indications
Mechanism of action
- Interleukin-23 subunit alphaSupplementation
IL23A supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06274554 | Phase 3 | Oct 4, 2024 | Cornell University, The Leona M. and Harry B. Helmsley Charitable Trust |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| The Leona M. and Harry B. Helmsley Charitable Trust | Academic/Hospital | 1 | 0 | 1 | 2024 |
2 organizations
Page 1 / 1